RETA Reata Pharmaceuticals Inc

Price (delayed)

$79.07

Market cap

$2.87B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.73

Enterprise value

$2.09B

Sector: Healthcare
Industry: Biotechnology

Highlights

RETA's quick ratio has soared by 119% YoY
Reata Pharmaceuticals's debt has plunged by 100% YoY
The company's equity has surged by 62% YoY but it fell by 12% QoQ
Reata Pharmaceuticals's EPS has increased by 23% YoY but it has decreased by 5% from the previous quarter
Reata Pharmaceuticals's gross profit has shrunk by 57% YoY and by 4.5% QoQ
Reata Pharmaceuticals's revenue has plunged by 57% YoY and by 4.5% from the previous quarter

Key stats

What are the main financial stats of RETA
Market
Shares outstanding
36.28M
Market cap
$2.87B
Enterprise value
$2.09B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.75
Price to sales (P/S)
332.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
242.84
Earnings
Revenue
$8.61M
EBIT
-$213.87M
EBITDA
-$212.74M
Free cash flow
-$327.21M
Per share
EPS
-$7.73
Free cash flow per share
-$9.04
Book value per share
$10.2
Revenue per share
$0.24
TBVPS
$22.51
Balance sheet
Total assets
$815.08M
Total liabilities
$445.75M
Debt
$0
Equity
$369.33M
Working capital
$691.16M
Liquidity
Debt to equity
0
Current ratio
7.04
Quick ratio
6.8
Net debt/EBITDA
3.66
Margins
EBITDA margin
-2,470.9%
Gross margin
100%
Net margin
-3,092.5%
Operating margin
-2,484%
Efficiency
Return on assets
-36.3%
Return on equity
-88.4%
Return on invested capital
N/A
Return on capital employed
-30.5%
Return on sales
-2,484%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RETA stock price

How has the Reata Pharmaceuticals stock price performed over time
Intraday
0.92%
1 week
-6.71%
1 month
-12.99%
1 year
-48.91%
YTD
-36.04%
QTD
-20.69%

Financial performance

How have Reata Pharmaceuticals's revenue and profit performed over time
Revenue
$8.61M
Gross profit
$8.61M
Operating income
-$213.87M
Net income
-$266.27M
Gross margin
100%
Net margin
-3,092.5%
Reata Pharmaceuticals's net margin has plunged by 101% YoY and by 13% from the previous quarter
Reata Pharmaceuticals's gross profit has shrunk by 57% YoY and by 4.5% QoQ
Reata Pharmaceuticals's revenue has plunged by 57% YoY and by 4.5% from the previous quarter
RETA's operating margin has dropped by 54% year-on-year

Growth

What is Reata Pharmaceuticals's growth rate over time

Valuation

What is Reata Pharmaceuticals stock price valuation
P/E
N/A
P/B
7.75
P/S
332.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
242.84
Reata Pharmaceuticals's EPS has increased by 23% YoY but it has decreased by 5% from the previous quarter
The company's equity has surged by 62% YoY but it fell by 12% QoQ
The stock's price to book (P/B) is 48% less than its last 4 quarters average of 15.0
The P/S is 165% above the 5-year quarterly average of 125.7 but 17% below the last 4 quarters average of 401.5
Reata Pharmaceuticals's revenue has plunged by 57% YoY and by 4.5% from the previous quarter

Efficiency

How efficient is Reata Pharmaceuticals business performance
The ROE has soared by 73% YoY and by 5% QoQ
Reata Pharmaceuticals's ROS has plunged by 54% YoY
RETA's return on assets is up by 44% year-on-year

Dividends

What is RETA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RETA.

Financial health

How did Reata Pharmaceuticals financials performed over time
RETA's total assets is 83% more than its total liabilities
RETA's quick ratio has soared by 119% YoY
The current ratio has surged by 117% year-on-year
Reata Pharmaceuticals's debt is 100% less than its equity
The debt to equity has plunged by 100% YoY
Reata Pharmaceuticals's debt has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.